Business
Hemostemix Confirms OTCQB Application is Filed
Calgary, Alberta--(Newsfile Corp. - October 19, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTX...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Confirms OTCQB Application is FiledCalgary, Alberta--(Newsfile Corp. - October 19, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) (\"Hemostemix\" or the \"Company\") is pleased to announce it filed with the compliance department of OTCQB all documentation required to up-list the Company's common shares on the OTCQB. The Company's application is under review. The common shares of Hemostemix will continue to trade on the Borse Frankfurt under the symbol \"2VFO\" and trade on the TSX Venture Exchange under the symbol \"HEM\".ABOUT OTCQBThe OTCQB is recognized by the SEC as an established public market. As a verified market with efficient access to broker-dealers, Funds and U.S. investors, the OTCQB helps companies build shareholder value, enhance liquidity, and achieve a fair valuation. Investors get an exchange-comparable information experience, with convenient trading through their preferred broker or financial advisor, transparent pricing with real-time quotes, and trusted disclosure. The financial portals and online brokerages that display the OTCQB market designations include CNBC.com, Money.CNN.com, ETRADE.com, FT.com, OTCMarkets.com, Schwab.com, Scottrade.com, SeekingAlpha.com, Sharebuilder.com, SNL.com, TDAmeritrade.com, Tradeking.com, and TMX.com. Blue Sky compliant, OTCQB companies may subscribe to the OTCQB Blue Sky Monitoring Services to monitor their status in real-time, to increase liquidity and expand investment advisors' ability to research and recommend the security.The OTCQB offers introductions to best-in-class equity research and offers visibility services such as investor relations solutions and the OTCQB podcast series, to provide a cost-effective suite of news, compliance, investor relations, and communications services. HEMOSTEMIXHemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted al...